Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22882
Title: | Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. | Austin Authors: | Dhiman, Kunal;Gupta, Veer Bala;Villemagne, Victor L ;Eratne, Dhamidhu;Graham, Petra L;Fowler, Christopher;Bourgeat, Pierrick;Li, Qiao-Xin;Collins, Steven;Bush, Ashley I;Rowe, Christopher C ;Masters, Colin L ;Ames, David;Hone, Eugene;Blennow, Kaj;Zetterberg, Henrik;Martins, Ralph N | Affiliation: | Centre for Economic Impacts of Genomic Medicine (GenIMPACT) Macquarie University Sydney NSW Australia Academic Unit for Psychiatry of Old age St. George's Hospital The University of Melbourne Australia KaRa Institute of Neurological Diseases Sydney NSW Australia Centre of Excellence in Alzheimer's Disease Research and Care School of Medical and Health Sciences Edith Cowan University Joondalup WA Australia Co-operative Research Centre for Mental Health Carlton Victoria Australia Australian Alzheimer's Research Foundation Ralph and Patricia Sarich Neuroscience Research Institute Nedlands WA Australia Department of Biomedical Sciences Macquarie University Sydney NSW Australia School of Psychiatry and Clinical Neurosciences University of Western Australia Perth WA Australia Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology Queen Square London UK UK Dementia Research Institute at UCL London UK Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden National Ageing Research Institute Parkville Victoria Australia Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia Florey Institute of Neuroscience and Mental Health Parkville Victoria Australia Melbourne Neuropsychiatry Centre University of Melbourne and NorthWestern Mental Health Parkville Victoria Australia CSIRO Health and Biosecurity Brisbane Australia School of Medicine Deakin University Victoria Australia Department of Medicine University of Melbourne Melbourne Victoria Australia |
Issue Date: | 27-Feb-2020 | Date: | 2020-02-27 | Publication information: | Alzheimer's & dementia (Amsterdam, Netherlands) 2020; 12(1): e12005 | Abstract: | This study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation. CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P < .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition. CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/22882 | DOI: | 10.1002/dad2.12005 | ORCID: | 0000-0002-5832-9875 | Journal: | Alzheimer's & dementia (Amsterdam, Netherlands) | PubMed URL: | 32211500 | ISSN: | 2352-8729 | Type: | Journal Article | Subjects: | ELISA amyloid biomarker dementia diagnosis neurodegeneration neurofilaments |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.